Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: J R Hagan who wrote (15605)	11/23/1999 11:14:00 PM
From: Kaliico	Respond to of 57584

How long till the seams bust loose on COOL ? Saw this post over at TJ thread...thanks to the author for DD. To: TokyoMex (0 ) From: Stockalysis Tuesday, Nov 23 1999 9:33PM ET Reply # of 111082 COOL rated #1 place to shop for computers by 5 major publications. Voted #1 hardware - editors choice by PC Magazine zdnet.com 0,6755,2354120,00.html Voted #1 USA Today usatoday.com Voted #1 by Bizrate bizrate.com COOL rated #1 site for Software, Computers and Electronics by Kiplinger kiplinger.com. COOL rated #1 place to shop for computers by The Wall Street Journal, in Monday Nov 22nd edition. Insiders have purchased over 200,000 shares in the last 6 weeks biz.yahoo.com Holiday 1999 Expected to Set New Records for Online Sales biz.yahoo.com COOL increases gross margin, on track to be profitable Message 11799643

To: J R Hagan who wrote (15605)	11/23/1999 11:34:00 PM
From: HeatherN	Read Replies (1) \| Respond to of 57584

J R Hagan, I know you had directed your question to DlphcOracl, but may I offer another opinion.... That drug is in trials to specifically treat sarcoma, which affects about 8000 people per year. If it is successful in some patients.....and if it were to be approved by the FDA.... it would still be a long time to profits. Small biotechs and treatments for diseases affecting small numbers of people are fabulous for the patients.... but entirely a crap shoot for investors. Even if it worked on every patient, the revenues would not be significant enough to warrant a huge jump in the stock price....the numbers are too small. Unless one is intimate with the company or the investigators, I would suggest that there are many, many better opportunities for profit. Rande has about 25 suggestions for us..... Peter Lynch advocates "buying what you know".....but this can also be interpreted as knowing what to avoid. I'm not anti-biotechs....you just need to really, really know the company, the technology and the target market. I'd like DlphcOracl's views on this topic too.... HeatherN